Racial and ethnic diversity in Janus kinase inhibitor alopecia areata clinical trials

Alopecia areata (AA) is a chronic autoimmune disease that causes non-scarring alopecia. In June 2022, baricitinib, a Janus kinase (JAK) inhibitor, became the first Federal Drug Administration (FDA) approved medication for adult patients with severe AA. This study aimed to analyze published JAK inhibitor alopecia areata randomized controlled trials to characterize and assess the racial and ethnic representation of participants. Attached below is a document listing the clinical trials assessed in our study.

斑秃（Alopecia areata，简称AA）是一种慢性自身免疫性疾病，导致非瘢痕性脱发。2022年6月，巴瑞替尼（Baricitinib），一种Janus激酶（JAK）抑制剂，成为首个由美国食品药品监督管理局（Federal Drug Administration，简称FDA）批准用于治疗成人严重斑秃的药物。本研究旨在分析已发表的JAK抑制剂斑秃随机对照试验，以描述和评估参与者的种族和民族代表性。以下附有本研究评估的临床试验清单文件。